SCHEMBL20072599

SCHEMBL20072599

CC(c1cc2c(Cl)cccc2nc1-c1cccc(F)c1)N1C(=O)c2ccccc2C1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.39
CYP2C9 P11712 4/20 0.39
CYP2D6 P10635 1/20 0.39
TACR3 P29371 9/20 0.36
USP2 O75604 3/20 0.35
CYP1A2 P05177 3/20 0.35
CYP2C19 P33261 3/20 0.35
MAPK1 P28482 2/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
KMT2A Q03164 1/20 0.35
ADORA2A P29274 1/20 0.35
HSD17B10 Q99714 2/20 0.35
TSHR P16473 1/20 0.35
PTGS2 P35354 1/20 0.35
CTSA P10619 1/20 0.34
MAOB P27338 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
NT5E P21589 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19788596 0.84 HPGD (0.39) MEN1ALDH1A1KMT2AHSD17B10TSHR
SCHEMBL4175806 0.83 ADORA2A (0.40) CYP3A4CYP2C9TACR3USP2CYP1A2
SCHEMBL4170998 0.75 NT5E (0.44) CYP3A4CYP2C9TACR3USP2CYP1A2
SCHEMBL4178011 0.73 ADORA2A (0.47) CYP3A4CYP2D6TACR3CYP1A2ALDH1A1
SCHEMBL12605690 0.72 NPC1 (0.37) CYP3A4CYP2C9CYP2D6CYP2C19MEN1
SCHEMBL20072535 0.71 HPGD (0.40) MEN1ALDH1A1KMT2AHSD17B10TSHR
SCHEMBL12974145 0.71 NT5E (0.38) CYP3A4CYP2C9USP2CYP1A2CYP2C19
SCHEMBL21705933 0.70 HPGD (0.37) MEN1ALDH1A1KMT2AHSD17B10TSHR
SCHEMBL19788597 0.70 PIK3CD (0.36) MEN1ALDH1A1KMT2AHSD17B10LMNA
SCHEMBL21705350 0.70 HPGD (0.48) CYP3A4CYP2C9CYP2D6USP2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180105532-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180105532-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 CYP3A4 3267/4885CYP2C9 2845/4885CYP2D6 2966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.